- Home
- AMBI vs NLSP Comparison
AMBI vs NLSP Comparison
Compare AMBI & NLSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMBI
- NLSP
- Stock Information
- Founded
- AMBI 1995
- NLSP 2015
- Country
- AMBI Brazil
- NLSP Switzerland
- Employees
- AMBI N/A
- NLSP N/A
- Industry
- AMBI Environmental Services
- NLSP Biotechnology: Pharmaceutical Preparations
- Sector
- AMBI Industrials
- NLSP Health Care
- Exchange
- AMBI Nasdaq
- NLSP Nasdaq
- Market Cap
- AMBI 327.6M
- NLSP 243.8M
- IPO Year
- AMBI N/A
- NLSP 2021
- Fundamental
- Price
- AMBI $5.66
- NLSP $4.59
- Analyst Decision
- AMBI
- NLSP
- Analyst Count
- AMBI 0
- NLSP 0
- Target Price
- AMBI N/A
- NLSP N/A
- AVG Volume (30 Days)
- AMBI 6.4K
- NLSP 32.4K
- Earning Date
- AMBI 01-01-0001
- NLSP 10-25-2024
- Dividend Yield
- AMBI N/A
- NLSP N/A
- EPS Growth
- AMBI 3161.09
- NLSP N/A
- EPS
- AMBI 0.56
- NLSP N/A
- Revenue
- AMBI $504,573,816.00
- NLSP N/A
- Revenue This Year
- AMBI N/A
- NLSP N/A
- Revenue Next Year
- AMBI N/A
- NLSP N/A
- P/E Ratio
- AMBI $10.58
- NLSP N/A
- Revenue Growth
- AMBI 25.13
- NLSP N/A
- 52 Week Low
- AMBI $3.07
- NLSP $4.08
- 52 Week High
- AMBI $8.44
- NLSP $35.52
- Technical
- Relative Strength Index (RSI)
- AMBI 58.05
- NLSP 38.85
- Support Level
- AMBI $4.99
- NLSP $4.10
- Resistance Level
- AMBI $6.42
- NLSP $5.36
- Average True Range (ATR)
- AMBI 0.41
- NLSP 0.54
- MACD
- AMBI 0.05
- NLSP -0.01
- Stochastic Oscillator
- AMBI 61.17
- NLSP 27.27
About AMBI Ambipar Emergency Response
Ambipar Emergency Response is a environmental, emergency response and industrial field service provider in Brazil with presence in 16 countries in Latin America, North America, Europe, Africa and Antarctica. The company provides customers with a full suite of environmental services organized around prevention, training and emergency response on all transportation modes. The portfolio includes a broad variety of services such as environmental remediation, industrial field services, industrial cleaning of chemical and non-chemical products and of hazardous and non-hazardous waste, consulting services focused on accident prevention and environmental licensing.
About NLSP NLS Pharmaceutics Ltd.
NLS Pharmaceutics Ltd is a biopharmaceutical company. It is engaged in the discovery and development of life-improving drug therapies to treat rare and complex CNS disorders. It focuses on developing therapeutics for the treatment of neurobehavioral and neurocognitive disorders. The company's tangible assets are held in the United States. Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.